keyword
https://read.qxmd.com/read/37871984/twenty-four-month-real-life-treatment-outcomes-of-polypoidal-choroidal-vasculopathy-versus-type-1-macular-neovascularization-in-caucasians
#21
JOURNAL ARTICLE
Matteo Airaldi, Alessandro Invernizzi, Vuong Nguyen, Stela Vujosevic, Federico Ricci, Pietro Monaco, Marco Nassisi, Daniel Barthelmes, Mark Gillies, Francesco Viola
BACKGROUND: To compare 24-month real-world outcomes of Vascular Endothelial Growth Factor (VEGF) inhibitors for Polypoidal Choroidal Vasculopathy (PCV) and type 1 Macular Neovascularization (MNV) in a Caucasian population. METHODS: Retrospective analysis from a prospectively designed observational database. Data from Italian centres participating in the Fight Retinal Blindness! (FRB!) project were collected. Treatment-naïve PCV or type 1 MNV commencing treatment after January 2009 were included...
November 2023: Clinical & Experimental Ophthalmology
https://read.qxmd.com/read/37853106/associations-of-presenting-visual-acuity-with-morphological-changes-on-oct-in-neovascular-age-related-macular-degeneration-precise-study-report-2
#22
JOURNAL ARTICLE
Shruti Chandra, Sarega Gurudas, Benjamin J L Burton, Geeta Menon, Ian Pearce, Martin Mckibbin, Ajay Kotagiri, James Talks, Anna Grabowska, Faruque Ghanchi, Richard Gale, Andrea Giani, Victor Chong, Taffeta Ching Ning Yamaguchi, Bishwanath Pal, Sridevi Thottarath, Raheeba Muhamed Pakeer, Swati Chandak, Andrea Montesel, Sobha Sivaprasad
PURPOSE: To study associations of optical coherence tomography (OCT) features with presenting visual acuity (VA) in treatment naive neovascular age-related macular degeneration (nAMD). METHODS: Patients with nAMD initiated on aflibercept therapy were recruited from December 2019 to August 2021. Demographic and OCT (Spectralis, Heidelberg Engineering) features associated with good VA (VA ≥ 68 ETDRS letters, Snellen ≥ 6/12) and poor VA (VA < 54 letters, Snellen < 6/18) were analysed using Generalised Estimating Equations to account for inter-eye correlation...
October 18, 2023: Eye
https://read.qxmd.com/read/37803144/macular-neovascularization-and-polypoidal-choroidal-vasculopathy-phenotypic-variations-pathogenic-mechanisms-and-implications-in-management
#23
REVIEW
Chui Ming Gemmy Cheung
Advances in imaging have led to improved ability to characterize variations in clinical sub-phenotypes of macular neovascularization (MNV) in Age-related macular degeneration (AMD). Polypoidal choroidal vasculopathy (PCV) was initially described based on characteristic features observed in indocyanine green angiography (ICGA) and was thought to be a distinct entity from AMD. However, subsequent careful observations based on confocal scanning laser ophthalmoscopy-based ICGA, optical coherence tomography (OCT) and OCT angiography have led researchers to appreciate similarities between PCV lesion and type 1 MNV in typical neovascular AMD...
October 6, 2023: Eye
https://read.qxmd.com/read/37800778/visual-outcomes-of-early-and-late-vitrectomy-for-breakthrough-vitreous-hemorrhage-associated-with-exudative-age-related-macular-degeneration-and-polypoidal-choroidal-vasculopathy
#24
JOURNAL ARTICLE
Pichai Jirarattanasopa, Natthaya Khongsakdinasarn, Mansing Ratanasukon, Patama Bhurayanontachai, Wantanee Dangboon Tsutsumi
To compare the visual outcomes of early and late vitrectomy for breakthrough vitreous hemorrhage (VH) associated with exudative age-related macular degeneration (exudative AMD) and polypoidal choroidal vasculopathy (PCV). A retrospective chart review was performed with data of all patients diagnosed with exudative AMD and PCV-related breakthrough VH who underwent early or late vitrectomy (within or after 3 months, respectively). Demographic data and best-corrected visual acuity (BCVA) at baseline, and 1, 3, 6, and 12 months postoperatively were recorded and analyzed...
October 6, 2023: Medicine (Baltimore)
https://read.qxmd.com/read/37773436/macular-lesions-associated-with-age-related-macular-degeneration-in-pachydrusen-eyes
#25
JOURNAL ARTICLE
Seung Wan Nam, Hoon Noh, Je Moon Yoon, Mingui Kong, Don-Il Ham
BACKGROUND: To investigate the prevalence of macular lesions associated with age-related macular degeneration (AMD) in eyes with pachydrusen. METHODS: Clinical records and multimodal imaging data of patients over 50 years old with drusen or drusenoid deposits were retrospectively assessed, and eyes with pachydrusen were included in this study. The presence of AMD features, including drusen or drusenoid deposits, macular pigmentary abnormalities, geographic atrophy (GA), and macular neovascularization (MNV), were evaluated...
September 29, 2023: Eye
https://read.qxmd.com/read/37696869/contribution-of-common-and-rare-variants-to-asian-neovascular-age-related-macular-degeneration-subtypes
#26
JOURNAL ARTICLE
Qiao Fan, Hengtong Li, Xiaomeng Wang, Yih-Chung Tham, Kelvin Yi Chong Teo, Masayuki Yasuda, Weng Khong Lim, Yuet Ping Kwan, Jing Xian Teo, Ching-Jou Chen, Li Jia Chen, Jeeyun Ahn, Sonia Davila, Masahiro Miyake, Patrick Tan, Kyu Hyung Park, Chi Pui Pang, Chiea Chuan Khor, Tien Yin Wong, Yasuo Yanagi, Chui Ming Gemmy Cheung, Ching-Yu Cheng
Neovascular age-related macular degeneration (nAMD), along with its clinical subtype known as polypoidal choroidal vasculopathy (PCV), are among the leading causes of vision loss in elderly Asians. In a genome-wide association study (GWAS) comprising 3,128 nAMD (1,555 PCV and 1,573 typical nAMD), and 5,493 controls of East Asian ancestry, we identify twelve loci, of which four are novel ([Formula: see text]). Substantial genetic sharing between PCV and typical nAMD is noted (rg = 0.666), whereas collagen extracellular matrix and fibrosis-related pathways are more pronounced for PCV...
September 11, 2023: Nature Communications
https://read.qxmd.com/read/37663754/serum-amyloid-a-4-as-a-common-marker-of-persistent-inflammation-in-patients-with-neovascular-age-related-macular-degeneration-and-polypoidal-choroidal-vasculopathy
#27
JOURNAL ARTICLE
Qingyan Liu, Shuo Sun, Zhengwei Yang, Yan Shao, Xiaorong Li
BACKGROUND: Neovascular age-related macular degeneration (nAMD) and its subtype, polypoidal choroidal vasculopathy (PCV), are common choroidal vasculopathies. Although they share many common clinical manifestations and treatment strategies, a lack of comprehensive analysis of these conditions means that it is difficult for researchers to further explore the common pathomechanisms of nAMD and PCV. The aim of this study was to characterize aqueous humor (AH) proteome alterations and identify a novel biomarker related to both nAMD and PCV...
2023: Journal of Inflammation Research
https://read.qxmd.com/read/37635588/low-rates-of-optical-coherence-tomography-utilization-in-the-diagnosis-and-management-of-retinovascular-diseases-in-a-lower-middle-income-economy
#28
JOURNAL ARTICLE
O N Okonkwo, A O Hassan, T Bogunjoko, A Akinye, T Akanbi, C Agweye
BACKGROUND: Optical coherence tomography (OCT) is widely used as the standard of care in evaluating macular and retinovascular diseases. However, the degree of OCT utilization is yet to be researched in a resource-limited country where wide gaps exist in access to healthcare. AIM: To determine the rate of utilization of the OCT in diagnosis, pre-treatment, and post-treatment evaluation of macular and retinovascular diseases treated with intravitreal anti-vascular endothelial growth factor injection (IVI)...
July 2023: Nigerian Journal of Clinical Practice
https://read.qxmd.com/read/37629406/differences-in-central-and-peripheral-choroidal-thickness-among-the-subtypes-of-age-related-macular-degeneration-in-an-asian-population
#29
JOURNAL ARTICLE
Yosuke Fukuda, Shoji Notomi, Satomi Shiose, Kumiko Kano, Sawako Hashimoto, Kohta Fujiwara, Masato Akiyama, Keijiro Ishikawa, Toshio Hisatomi, Koh-Hei Sonoda
Age-related macular degeneration (AMD) causes visual impairment in individuals who are >50 years of age. However, no study has investigated AMD when using ultra-wide-field swept-source optical coherence tomography (UWF SS-OCT). We aimed to evaluate central and peripheral choroidal thicknesses using UWF SS-OCT, and to compare these across the AMD subtypes. We included 75 eyes of patients with typical AMD (tAMD), 56 with polypoidal choroidal vasculopathy (PCV), 29 with pachychoroid neovasculopathy (PNV), and 12 with retinal angiomatous proliferation (RAP)...
August 18, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37510825/long-term-prognosis-of-patients-with-polypoidal-choroidal-vasculopathy-treated-with-photodynamic-therapy
#30
JOURNAL ARTICLE
Yukinori Sakaeda, Aki Kato, Soichiro Kuwayama, Shuichiro Hirahara, Norihiro Suzuki, Yuichiro Ogura, Yoko Nakazawa, Tsutomu Yasukawa
We evaluated the long-term prognosis of the eyes of patients with polypoidal choroidal vasculopathy (PCV) treated with photodynamic therapy (PDT). In total, 60 eyes of 57 patients diagnosed with PCV and treated with PDT were reviewed retrospectively in real-world settings. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), anatomical findings (vision-threatening findings), and treatment history were assessed. In total, 38 eyes underwent PDT as the initial treatment (initial PDT group) and 22 eyes underwent PDT as a rescue treatment (rescue PDT group)...
July 16, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37504966/intravitreal-brolucizumab-and-aflibercept-for-polypoidal-choroidal-vasculopathy
#31
JOURNAL ARTICLE
Han Joo Cho, Kyoung Hae Kang, Wontae Yoon, Jihyun Lee, Chul Gu Kim, Jong Woo Kim
Purpose: To compare the effectiveness of intravitreal injections of brolucizumab and aflibercept in patients with polypoidal choroidal vasculopathy (PCV). Methods: In total, 62 treatment-naive PCV eyes (62 patients) treated with intravitreal brolucizumab or aflibercept were analyzed retrospectively. All patients received a monthly loading injection of antivascular endothelial growth factor for 3 months, followed by further injections as required. Visual and anatomical outcomes were compared between drugs after 12 months of treatment...
July 27, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37492247/discontinuation-of-treatment-and-retreatment-of-neovascular-age-related-macular-degeneration-in-the-real-world-bundang-amd-cohort-study-report-5
#32
JOURNAL ARTICLE
Soo Chang Cho, Kyu Hyung Park, Sang Jun Park, Kwangsic Joo, Se Joon Woo
INTRODUCTION: This single-center retrospective cohort study investigated the incidence rate and risk factors for the discontinuation of anti-vascular endothelial growth factor (VEGF) injections and retreatment in typical neovascular age-related macular degeneration (tnAMD) and polypoidal choroidal vasculopathy (PCV) in the real-world setting. METHODS: A total of 488 eyes with either tnAMD ( n = 334) or PCV ( n = 154) followed up for ≥3 years were analyzed...
2023: Frontiers in Medicine
https://read.qxmd.com/read/37295608/anti-vegf-treatment-strategies-on-three-subtypes-of-neovascular-age-related-macular-degeneration-in-real-world-clinical-setting-a-multicenter-cohort-study-in-japan
#33
JOURNAL ARTICLE
Keisuke Yoneda, Masaru Takeuchi, Tsutomu Yasukawa, Hiroto Terasaki, Yuki Yamamoto, Tatsuya Jujo, Makiko Wakuta, Hisashi Matsubara, Yoshinori Mitamura, Aki Kato, Mineo Kondo, Kazuhiro Kimura, Hitoshi Takagi, Fumi Gomi, Taiji Sakamoto
PURPOSE: Neovascular age-related macular degeneration (nAMD) is classified into typical AMD (tAMD), polypoidal choroidal vasculopathy (PCV), and retinal angiomatous proliferation (RAP). This study investigated clinical features of the three subtypes and visual outcome associated with real-world treatment regimens in a large cohort of nAMD patients. DESIGN: Retrospective multicenter cohort study PARTICIPANTS: Five hundred treatment-naïve nAMD (268 tAMD, 200 PCV, and 32 RAP) patients initiated with anti-VEGF agents and followed for 1 year...
June 7, 2023: Ophthalmology Retina
https://read.qxmd.com/read/37263796/chinese-guideline-for-the-management-of-polypoidal-choroidal-vasculopathy-2022
#34
JOURNAL ARTICLE
You-Xin Chen, Yu-Qing Zhang, Chang-Zheng Chen, Hong Dai, Su-Yan Li, Xiang Ma, Xiao-Dong Sun, Shi-Bo Tang, Yu-Sheng Wang, Wen-Bin Wei, Feng Wen, Ge-Zhi Xu, Wei-Hong Yu, Mei-Xia Zhang, Ming-Wei Zhao, Yang Zhang, Fang Qi, Xun Xu, Xiao-Xin Li
Background In mainland China, patients with neovascular age-related macular degeneration (nAMD) have an approximately 40% prevalence of polypoidal choroidal vasculopathy (PCV). This disease leads to polys, recurrent retinal pigment epithelium detachment (PED), extensive subretinal or vitreous hemorrhages, and severe vision loss. China has introduced various treatment modalities in the past years, and gaining comprehensive experience in treating PCV is necessary. Methods A total of 14 retinal specialists nationwide with expertise in PCV were empaneled to prioritize six questions and address their corresponding outcomes, regarding opinions on inactive PCV, choices of anti-vascular endothelial growth factor (anti-VEGF) monotherapy, photodynamic therapy (PDT) monotherapy or combined therapy, patients with persistent subretinal fluid (SRF) or intraretinal fluid (IRF) after loading dose anti-VEGF, or patients with massive subretinal hemorrhage...
May 31, 2023: Chinese Medical Sciences Journal
https://read.qxmd.com/read/37253802/three-month-outcomes-of-faricimab-loading-therapy-for-wet-age-related-macular-degeneration-in-japan
#35
MULTICENTER STUDY
Ryo Mukai, Keiko Kataoka, Koji Tanaka, Yasunori Miyara, Ichiro Maruko, Makiko Nakayama, Yuto Watanabe, Akiko Yamamoto, Yu Wakatsuki, Hajime Onoe, Sorako Wakugawa, Nobuhiro Terao, Taiji Hasegawa, Nozomu Hashiya, Moeko Kawai, Ruka Maruko, Kanako Itagaki, Jyunichiro Honjo, Annabelle A Okada, Ryusaburo Mori, Hideki Koizumi, Tomohiro Iida, Tetsuju Sekiryu
This multicenter study aimed to assess the short-term effectiveness and safety of faricimab in treatment-naïve patients with wet age-related macular degeneration (wAMD) in Japan. We retrospectively reviewed 63 eyes of 61 patients with wAMD, including types 1, 2, and 3 macular neovascularization as well as polypoidal choroidal vasculopathy (PCV). Patients received three consecutive monthly intravitreal injections of faricimab as loading therapy. Over these 3 months, visual acuity improved gradually compared to baseline...
May 30, 2023: Scientific Reports
https://read.qxmd.com/read/37238165/new-concepts-for-the-diagnosis-of-polypoidal-choroidal-vasculopathy
#36
REVIEW
Jinzhi Zhao, Priya R Chandrasekaran, Kai Xiong Cheong, Mark Wong, Kelvin Teo
Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (nAMD) that is characterized by a branching neovascular network and polypoidal lesions. It is important to differentiate PCV from typical nAMD as there are differences in treatment response between subtypes. Indocyanine green angiography (ICGA) is the gold standard for diagnosing PCV; however, ICGA is an invasive detection method and impractical for extensive use for regular long-term monitoring. In addition, access to ICGA may be limited in some settings...
May 9, 2023: Diagnostics
https://read.qxmd.com/read/36959460/clinical-variations-of-polypoidal-choroidal-vasculopathy-a-cohort-study-from-japan-and-the-usa
#37
JOURNAL ARTICLE
Hisashi Fukuyama, Ghazi BouGhanem, John Moir, Dimitra Skondra, Fumi Gomi, Amani A Fawzi
We describe the clinical characteristics of treatment-naïve polypoidal choroidal vasculopathy (PCV) in three tertiary clinic settings in 2 cities (Chicago in the USA and Nishinomiya in Japan). This cohort study was a retrospective, multicenter, consecutive case series. A total of 126 patients with treatment-naïve PCV-46 in Chicago and 80 in Nishinomiya-were identified. The proportion of PCV in patients with neovascular age-related macular degeneration was lower in Chicago (10.8% vs. 36.9%). Patients in Chicago had a significantly higher prevalence of soft drusen (50...
March 23, 2023: Scientific Reports
https://read.qxmd.com/read/36911383/vortex-vein-engorgement-and-different-shapes-of-venous-drainage-systems-in-polypoid-choroidal-vasculopathy-vs-age%C3%A2-related-macular-degeneration-on-indocyanine-green-angiography
#38
JOURNAL ARTICLE
Chen-Xi Cai, Xiao-Mei Xiong, Tao Li, Bing-Qian Liu, Xin-Hua Huang, Shan-Shan Yu, Zhen-Qiang Lin, Qiang Wang, Jin-Li Cui, Lin Lu, Ying Lin
There are differences in vortex vein engorgement and appearance in polypoid choroidal vasculopathy (PCV), age-related macular degeneration (AMD), and healthy eyes. The present study aimed to use indocyanine green angiography (ICGA) to find a simple, clinically meaningful method for evaluating the filling degree of vortex veins in various eye diseases. Participant clinical characteristics were recorded. The number of vortex veins (NVV), central vortex vein diameter (CVVD), mean root area of the vortex vein (MRAVV), mean diameter of the thickest peripheral branch (MDPTB), subfoveal choroidal thickness and percentage of vortex vein anastomosis (PVVA) were obtained by marking the vortex veins on ICGA...
April 2023: Experimental and Therapeutic Medicine
https://read.qxmd.com/read/36906669/serum-levels-of-il-4-il-13-and-il-33-in-patients-with-age-related-macular-degeneration-and-myeloproliferative-neoplasms
#39
JOURNAL ARTICLE
Kathrine Gotfredsen, Charlotte Liisborg, Vibe Skov, Lasse Kjær, Hans Carl Hasselbalch, Torben Lykke Sørensen
Immune responses play a key role in the pathogenesis and progression of myeloproliferative neoplasms (MPN) and age-related macular degeneration (AMD). Recent studies suggested using MPNs as a "Human Inflammation Model" of drusen development and previous results showed interleukin-4 (IL-4) dysregulation in MPN and AMD. IL-4, IL-13 and IL-33 are all cytokines involved in the type 2 inflammatory response. This study investigated the cytokine levels of IL-4, IL-13 and IL-33 in serum of MPN and AMD patients. This cross-sectional study included 35 patients with MPN with drusen (MPNd) and 27 with MPN and normal retinas (MPNn), 28 patients with intermediate AMD (iAMD) and 29 with neovascular AMD (nAMD)...
March 11, 2023: Scientific Reports
https://read.qxmd.com/read/36884066/-photodynamic-therapy-in-germany-quo-vadis
#40
JOURNAL ARTICLE
L Pauleikhoff, K Rothaus, F Groß-Bölting, D Böhringer, J Lübke, H Agostini, C Lange
BACKGROUND: Photodynamic therapy (PDT) was originally approved for the treatment of neovascular age-related macular degeneration (nAMD) and secondary choroidal neovascularization in myopia (mCNV). In addition, it is used as an off-label treatment in patients with choroidal hemangioma, polypoidal choroidal vasculopathy (PCV), and central serous chorioretinopathy (CSC). OBJECTIVE: To track the development of PDT treatment numbers in Germany between 2006 and 2021 and to investigate the composition of the therapeutic indications...
March 8, 2023: Ophthalmologie
keyword
keyword
41367
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.